Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.125
Bid: 8.00
Ask: 8.25
Change: 0.00 (0.00%)
Spread: 0.25 (3.125%)
Open: 8.125
High: 8.125
Low: 8.125
Prev. Close: 8.125
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IXICO plc announces SBRI Healthcare contract

16 Apr 2014 07:00

RNS Number : 9231E
IXICO plc
16 April 2014
 



16 April 2014

 

 

IXICO plc announces SBRI Healthcare development contract

 

IXICO plc (Ticker: IXI) ("IXICO" or the "Company"), the brain health company, announces that it has been awarded a development contract by SBRI Healthcare (The Small Business Research Initiative for Healthcare) to cover Phase 1 funding for the development of an online application designed to support dementia sufferers post-diagnosis.

Receiving a dementia diagnosis is inevitably traumatic for patients and far too often, patients and their families receive very little support until there is a crisis. This development project will build on Assessa™, IXICO's digital healthcare platform to support dementia diagnosis, to address post-diagnostic care planning and support. It aims to harness web and mobile technologies to provide ongoing support and to assist those living with dementia as well as their families, carers and healthcare professionals. The goal is to prolong and enhance independent living by facilitating improved self-care with full interaction with the relevant healthcare professionals and other support agencies. Social media concepts will be adapted to build a personal management tool whereby diagnosis is carefully linked to continuing care-planning and support. This will then aid the transition into other care settings by travelling with the patient and relatives throughout the course of the illness.

The project will be led by IXICO in partnership with the Health Innovation Network South London. (www.hin-southlondon.org)

Commenting on the award, Derek Hill, CEO of IXICO said:

 

'We are delighted to receive this support from SBRI Healthcare which will help us to extend the potential patient benefit of Assessa™ following diagnosis and is central to the widening of our digital healthcare offering. We look forward to working with the Health Innovation Network to improve the care of dementia sufferers.'

 

Commenting on the award, Dr Hugo DeWaal, Clinical Director for Dementia at the Health Innovation Network said:

 

'Dementia is a key health and social care priority, and the Health Innovation Network is keen to develop a tool that is helpful for people with dementia, their families and carers. We hope that this partnership and SBRI funding will allow us to rapidly improve dementia care for a greater number of people.'

About SBRI Healthcare

The Small Business Research Initiative for Healthcare (SBRI Healthcare) is an NHS England initiative, championed by the newly formed Academic Health Science Networks (AHSNs), that aim to promote UK economic growth whilst addressing unmet health needs and enhancing the take up of known best practice. Part of Innovation Health and Wealth, the SBRI Healthcare programme sets industry the challenge in a series of health related competitions which result in fully funded development contracts between the awarded company and the NHS. Unlike many R&D projects which offer grant or match funding, SBRI contracts are 100 per cent funded and the company retains the IP.

More information is available on www.sbrihealthcare.co.uk

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and more recently launched into the wider clinical diagnostic market. Since incorporation, IXICO has been awarded contracts by nine of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

About the Health Innovation Network

The Health Innovation Network is a membership organisation, driving lasting improvements in health and wellbeing across South London by sharing innovations across the health system and capitalising on teaching and research strengths. Founded by NHS England, the Health Innovation Network is the Academic Health Science Network (AHSN) for South London. We are focusing on health priorities for our local communities across a number of clinical areas and cross-cutting innovation themes, including dementia, diabetes, musculoskeletal, alcohol and cancer. www.hin-southlondon.org 

 

Enquiries:

 

IXICO plc

Derek Hill, CEO

Charles Spicer, VP Corporate Development

+44 20 7691 2064

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel

Clare Terlouw

+44 20 7418 8900

 

Daniel Stewart & Company (Joint Broker)

Mark Treharne

David Hart

+44 207 776 6550

 

FTI Consulting Limited (Investor Relations)

Ben Atwell

Simon Conway

John Dineen

+44 20 3727 1000 

 

Health Innovation Network

Anna King, Commercial Director

+44 20 7188 7188

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFDEDIFLSEFL
Date   Source Headline
15th Apr 20247:00 amRNSLife Molecular Imaging – Neuraceq Supply Agreement
3rd Apr 20247:00 amRNSImeka Collaboration Agreement
13th Mar 20247:00 amRNSTrading Update
29th Jan 202412:00 pmRNSHolding(s) in Company
25th Jan 20244:00 pmRNSResult of AGM
12th Jan 20249:35 amRNSDirectorate Change
27th Dec 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
15th Dec 20237:00 amRNSChange of Auditor
5th Dec 20237:00 amRNSFinancial Results for year ended 30 September 2023
27th Nov 20237:00 amRNSNotice of Results and Investor Presentation
5th Oct 20237:00 amRNSAppointment of Independent Non-Executive Director
29th Sep 20237:00 amRNSTrading Update
18th Jul 20237:00 amRNSContract Win
14th Jun 20237:00 amRNSContract Win
23rd May 20237:00 amRNSHalf year report
16th May 20237:00 amRNSInvestor Meet Company presentation
10th May 20237:00 amRNSTrading Update
3rd Apr 20238:35 amRNSExtension of Huntington's disease consortium
21st Mar 202312:11 pmRNSHolding(s) in Company
10th Mar 20237:00 amRNSContract Win
7th Feb 20237:00 amRNSTrading Update
31st Jan 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20232:05 pmRNSSecond Price Monitoring Extn
31st Jan 20232:00 pmRNSPrice Monitoring Extension
31st Jan 202311:05 amRNSSecond Price Monitoring Extn
31st Jan 202311:00 amRNSPrice Monitoring Extension
27th Jan 20231:00 pmRNSResult of AGM
3rd Jan 20237:00 amRNSTotal Voting Rights
22nd Dec 202212:18 pmRNSDirector Bed & ISA Dealing
13th Dec 20227:00 amRNSPDMR Exercise of Options
9th Dec 20229:05 amRNSContract Win
8th Dec 20223:34 pmRNSContract Update
7th Dec 20227:00 amRNSFinancial Results for the year ended 30 Sept 2022
21st Nov 20227:00 amRNSNotice of Results and Investor Presentation
25th Oct 20227:00 amRNSTrading Update
21st Sep 202210:35 amRNSHD-IH Consortium
14th Sep 20227:00 amRNSGrant of Share Options
1st Sep 20227:00 amRNSTrading Update and FY2023 Guidance
4th Aug 20227:00 amRNSContract Win
26th Jul 202211:22 amRNSContract Win - Replacement
21st Jul 20227:00 amRNSContract Win
14th Jun 20227:00 amRNSContract Extension
24th May 20227:00 amRNSHalf-year Report and Trading Update
16th May 20227:00 amRNSInvestor Presentation
10th May 20227:00 amRNSConsortium Agreement in Huntington's Disease
25th Apr 20227:00 amRNSTrading Update
21st Apr 20227:00 amRNSNew Contract Win
8th Mar 20227:00 amRNSContract worth circa £800k
14th Feb 20227:00 amRNSLaunch of IXIQ.Ai Deep learning AI-based platform
8th Feb 202212:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.